Malignant pleural effusion – European Respiratory Review
A malignant pleural effusion is a complication that involves the build-up of fluid containing cancer cells between the membranes that line the lungs. It occurs in around 30 percent of lung cancers, but can also occur with other cancers, such as breast cancer, ovarian cancer, leukemias, and lymphomas.With lung cancer, a malignant pleural effusion may be the first sign of cancer, or it can occur as a late complication of advanced lung cancer.
A pleural effusion is defined as an abnormal amount of fluid in the space between the layers of tissue (the pleura) that line the lungs. If cancer cells are present in this fluid (the pleural cavity), it is called a malignant(cancerous) pleural effusion.A malignant pleural effusion may be large and diffuse or small and involve just a small portion of the pleural cavity. The effusion may be all in one area, or there may be several areas of effusion (septated pleural effusions).
The symptoms of a malignant pleural effusion can be very uncomfortable. Shortness of breath is by far the most common symptom, occurring in around 80 percent of people. A cough may be present, and this is often positional, meaning it may be worse in certain positions such as with leaning forward or lying on one side. Chest pressure or some type of abnormal chest sensation may also occur.
Almost any type of cancer can cause a pleural effusion if it is present in or spreads (metastasizes) to the chest area. The most common are breast cancer, lung cancer, ovarian cancer, and some types of leukemias and lymphomas. A pleural effusion may also be caused by treatments for lung cancer, such as surgery, radiation therapy, or chemotherapy.
A malignant pleural effusion is a disease development that affects around 15 percent of people with cancer. It occurs in around 150,000 Americans with cancer each year and is generally associated with a poor outlook.
It is important to make an accurate diagnosis of a malignant pleural effusion since the prognosis and treatment are much different than for non-malignant (benign) pleural effusions. It’s important to note that even with cancer, up to 50 percent of pleural effusions are benign.A malignant pleural effusion is often first suspected because of symptoms or findings on a chest X-ray or CT scan. If your doctor suspects a malignant pleural effusion, the next step is usually a thoracentesis, a procedure in which a needle is inserted through the chest wall into the pleural space to get a sample of the fluid. This fluid is then examined under a microscope to see if cancer cells are present.If a thoracentesis cannot be done, or if the results are inconclusive, further procedures may need to be done to get an accurate diagnosis. In some cases, a thoracoscopy (a procedure in which a thoracoscope is inserted into the chest) may need to be done to obtain a biopsy to diagnose a malignant pleural effusion.Sadly, the average life expectancy for lung cancer with a malignant pleural effusion is less than six months. The median survival time (the time at which 50 percent of people will have died) is four months, though some people survive longer.The prognosis is slightly better for those who have malignant pleural effusions related to breast cancer or especially ovarian cancer. With the advent of newer treatments such as targeted therapies and immunotherapy, it is hoped that these numbers will change in the near future. There are also many clinical trials in progress looking at the optimal treatment for these effusions.
The goal in treating a malignant pleural effusion is most often palliative, that is, to improve quality of life and reduce symptoms but not to cure the malignancy. If the effusion is very small, it can sometimes be left alone.
Although thoracentesis is generally considered safe, complications such as infection, pneumothorax (collapsed lung), chest wall bleeding, blood clots, and re-expansion of the pulmonary edema are possible.
One procedure that works in roughly 60 to 90 percent of people is called a pleurodesis. In this procedure, a tube is inserted into the pleural space and a substance, commonly talc, is inserted between the two membranes lining the lungs. This chemical causes inflammation in the pleural cavity which in turn causes the two linings to stick together (fuse) preventing fluid from again accumulating in the pleural space. The possible complications of pleurodesis are similar to those of thoracentesis.
Indwelling Pleural Catheters
Another procedure is an indwelling pleural catheter (IPC), also known as a tunneled pleural catheter. In this procedure, a small tube is inserted into the pleural space and tunneled beneath the skin, with a small opening on your side which can be covered with a bandage. This allows people to drain their own fluid by attaching a vacuum container to the opening in the skin.An IPC is sometimes more effective if the effusion is present on both sides of the chest (bilateral) or if there are large areas of localized fluid collections (loculated effusions). This procedure is often considered less invasive than a pleurodesis and is effective in 80 percent to 100 percent of people. Many researchers now feel that IPCs should be considered first-line in all people with a malignant effusion.
An IPC may cause infection in less than 5 percent of users and can usually be treated with oral antibiotics. The larger concern is the long-term risk of catheter tract metastasis in which cancer cells are spread via the catheter.
Additional Treatment Options
Choosing the Appropriate Treatment
There has been debate over whether pleurodesis or an indwelling pleural catheter is the better option for people with advanced cancer and a recurrent pleural effusion.A 2017 study published in the Journal of the American Medical Association, sought to answer this question. The researchers found that those who had indwelling pleural catheters had fewer hospitalizations than those who had pleurodesis, primarily related to the need for procedures to remove pleural fluid.Otherwise, there were no significant differences in either the sensation of shortness of breath or the quality of life of participants.Before a pleurodesis or tunneled pleural catheter is recommended, a few things are necessary:
- First, your doctor will want to confirm that you have a malignant pleural effusion and that your symptoms are not due to another cause.
- Secondly, you should have a pleural effusion that recurs (returns) after a thoracentesis.
- Thirdly and most importantly, the draining of the fluid from your pleural space should help with your symptoms of shortness of breath.
It is not necessary to remove fluid just because it is there, but only if it is causing problems such as shortness of breath. If the shortness of breath is due to another cause, such as COPD, there is usually no benefit to removing the fluid.
The emotions you can experience when learning you have a malignant pleural effusion can be considerable. Pair that with the disease’s poor prognosis, and the experience can be distressing for anyone.To better cope, learn as much about the disease and the advancing research. Ask questions. Ask for help from others, and allow them to give it. Talk to your doctor about pain management options. Consider joining a support group.Your emotions may span the spectrum from anger to disbelief to depression. That is normal. Seek out friends and loved ones who are willing to truly listen and support you.7 Diseases Associated with Pleural Effusion